Several analysts have recently updated their ratings and price targets for Ayala Pharmaceuticals (OTCMKTS: ADXS):
- 6/21/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/19/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/18/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/17/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/15/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/14/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/13/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/11/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/10/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/9/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/7/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/1/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 5/30/2023 – Ayala Pharmaceuticals was upgraded by analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating.
- 5/25/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 5/20/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 5/12/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 5/4/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 4/26/2023 – Ayala Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of Ayala Pharmaceuticals stock opened at $0.97 on Friday. The stock has a 50 day moving average of $1.02 and a 200 day moving average of $1.16. The firm has a market capitalization of $1.76 million, a price-to-earnings ratio of -0.11 and a beta of 2.43. Ayala Pharmaceuticals, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $4.50.
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.
Further Reading
- Get a free research report on Ayala Pharmaceuticals from StockNews.com
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Darden Restaurants: Ring The Register Or Time To Buy?
- United Airlines: Cleared For Takeoff As It Approaches Buy Point?
- KB Home Hits Peak: Pullback Imminent
- Five stocks we like better than Ayala Pharmaceuticals
Receive News & Ratings for Ayala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
